A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

NCT06907043 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: EIK1004-001 (IMP1707-001)

Sponsor

Eikon Therapeutics

Collaborators

[object Object]